As the small molecules revolution continues to make “undruggable” targets “druggable”, the 5th TPD & Induced Proximity Summit Europe will offer 3 days of jam-packed content.
We are going to address your biggest challenges including, but not limited to:
Enhancing Oral Bioavailability of PROTACs:
Explore innovative strategies to improve the oral bioavailability of PROTACs, ensuring effective delivery and patient exposure
Developing Non-Degrading Proximity Therapeutics:
Gain insights into the development of non-degrading proximity therapeutics, realising the true therapeutic potential of small molecules and targeting novel diseases
Advancing Molecular Glue Discovery:
Delve into the latest techniques and platforms for accelerating and optimising molecular glue discovery to target previously undruggable proteins
Innovating Non-Ubiquitination and Non-Cytosolic Degraders:
Learn about cutting-edge approaches for lysosomal degraders as well as surface and ECM protein degradation, offering new avenues for therapeutic intervention and filling unmet needs
4 Reasons You Can’t Miss the World’s First Industry Dedicated Proteomics Summit:
Translate your targeted protein degraders into the clinic with insights on ADME, dosing, and patient selection challenges from Merck Healthcare KGaA, Foghorn Therapeutics, and Astellas Pharmaceuticals
Unlock previously untargeted disease targets and enable their degradation by expanding to effectors beyond traditional E3 ligases with pioneering discoveries by Phoremost, BPG Bio, and Innoxtal
Enable novel therapeutic interventions such as targeting
extracellular matrix and surface proteins and go beyond degradation with innovative molecules shared by Laigo Bio, Rapafusyn Pharmaceuticals
and Draupnir Bio
Accelerate PROTAC and molecular glue discovery by integrating AI for predicting surface complementarities, PK-PD profiles, and ternary structures developed by Vant AI, Sibylla Biotech and Ternary Therapeutics